To the Editors: MacKerrow and colleagues (1) reported on the ability of triiodothyronine to treat cardiogenic shock resulting from severe hypothyroidism (myxedema); however, certain points must be clarified.
First, the authors conclude that their patient had Sheehan syndrome because she was unable to lactate after her last pregnancy. In the absence of significant hemorrhage or obstetrical trauma, an equally likely diagnosis would be lymphocytic hypophysitis (2) , which would account for secondary adrenal and thyroid failure.
That the patient failed to improve and, in fact, worsened over the first 5 days while receiving therapy with oral L-thyroxine, 50 jLtg/d, is not surprising. As they suggest, hypothyroidism may impair the absorption of orally administered thyroid hormone. In addition, the doses of thyroxine were less than those usually required for inducing rapid cellular and clinical responses. This is confirmed by the failure of the serum thyroxine level to increase after 8 days of treatment.
Much of the hemodynamic improvement after triiodothyronine treatment can be explained by decreases in systemic vascular resistance. Recent observations suggest that one of the major sites of action of thyroid hormone is in the peripheral circulation and specifically at the level of regulating tone of vascular smooth muscle cells (3, 4) . If indeed these direct effects are relatively specific for triiodothyronine, then the current case would suggest that intravenous triiodothyronine may be the treatment of choice in severe hypothyroidism associated with impaired cardiac performance. Known or suspected coexistent ischemic heart disease, however, requires that the triiodothyronine dose be at physiologic replacement levels and that the patient be carefully monitored.
That the patient continued to manifest left ventricular dysfunction long after both the adrenal insufficiency and hypothyroidism were treated is consistent with our observation that true heart failure accompanying hypothyroidism should suggest underlying left ventricular dysfunction (5) .
Brenner BM, Kaplan NM, eds. Endocrine Mechanisms in Hypertension, v. 2. New York: Raven Press; 1989:61-80. 4 . Ojamaa K, Balkman C, Klein I. Acute effects of T 3 In response: Drs. Mantzoros and Ravi suggest the possibility of a beneficial response to thyroxine rather than to intravenous triiodothyronine. The following observations argue against any significant therapeutic contribution from the thyroxine: After 7 days of thyroxine therapy, the patient had hemodynamic measurements indicating cardiogenic shock; on day 8, both serum thyroxine and triiodothyronine levels were still abnormally low; and ". . . since T3 [triiodothyronine] has approximately three times the metabolic potency of T4 [thyroxine] , virtually all of the metabolic action of T4 can be ascribed to the action of the T3 that it gives rise to" (1) . We believe thyroxine could not give rise to triiodothyronine in our patient because of impaired conversion. These points, along with dramatic improvement 16 hours after administering intravenous triiodothyronine, with a then normal serum triiodothyronine level, support the belief that parenteral triiodothyronine was the definitive hormone therapy.
We agree with Drs. Mantzoros and Ravi that cautious thyroid hormone replacement therapy should be used if coronary ischemic heart disease is suspected. In our case report, we emphasize that heart failure caused by hypothyroidism is rare, but when it exists and is severe, intravenous triiodothyronine therapy is recommended. We are not proposing this treatment for patients with heart failure due to other causes who are concurrently hypothyroid.
We agree with Dr. Klein that the differential diagnosis of hypopituitarism should include lymphocytic hypophysitis. This disorder frequently is associated with elevated prolactin levels (2) . In the case we reported, the patient was unable to lactate after her last pregnancy, and she had an undetectable prolactin level. To completely resolve this question would require microscopic examination of the patient's pituitary gland.
Dr. Klein's comments about the potential role of triiodothyronine in lowering systemic vascular resistance are most intriguing (3). Other variables contributing to the falling systemic vascular resistance included decreased catecholamine levels after intubation with improved oxygenation and decreased work of breathing; and a reflex decrease in systemic vascular resistance after triiodothyronine-mediated improvement in myocardial contractility leading to improved cardiac output.
We agree with Dr. Klein about underlying left ventricular dysfunction in patients with heart failure and hypothyroidism. Given the return to normal of left ventricular systolic function with thyroid hormone replacement therapy and the absence of another etiologic factor, the cause could have been entirely hypothyroidism. The lag between establishment of normal serum thyroid hormone levels and recovery of normal left ventricular systolic performance suggests that significant time is required to re-establish normal myosin isoenzymes along with intracellular calcium kinetics (4, 5) . 
Management of the Severely Anemic Jehovah's Witness
To the Editors: Mann and colleagues (1) describe an intelligent and badly needed approach to the treatment of the anemic Jehovah's Witness. Their recommendations regarding the use of erythropoietin and iron dextran are both accurate and prudent. However, there is an error in their reference to our article (2): Iron dextran is and has been labeled for intravenous use; such use is restricted (under label) to undiluted, intravenous boluses not to exceed 100 mg. Our study clearly showed the superiority of total dose infusion of iron dextran given in 500 mL of normal saline over the approved (label) method of intravenous iron administration. Mann and coworkers point toward the usefulness of total dose infusion, but their admonition regarding the occurrence of two anaphylactic reactions in our study may create undue alarm. There were two acute reactions: A substance abuser experienced total body pain within seconds of the test dose; this was clearly an anxiety reaction but one that needed to be mentioned for the integrity of the study. A second person had a genuine acute hypersensitivity reaction, with wheezing and tachycardia but without hypotension or shock. This reaction abated within 30 minutes with administration of intravenous methylprednisolone. We have subsequently treated over 200 patients without an acute reaction. Furthermore, the acute reactions occurred with the test dose and do not relate to the method of iron dextran administration. Test doses are recommended with any form of parenteral iron administration, and acute reactions occur equally with intramuscular administration, intravenous bolus administration, and total dose infusion.
Our conclusion should therefore be underscored: If parenteral iron is indicated, it should be given as a total dose infusion. We believe clarifying this point solidifies the therapeutic recommendations in this extremely timely and wellwritten article. To the Editors: Albumin is added as a stabilizer to recombinant human erythropoietin and the newly licensed recombinant human antihemophilic factor. Mann and colleagues (1) state that the acceptance of albumin is an individual decision by Jehovah's Witnesses. However, in conversation with Church Elders, we have learned that albumin is considered acceptable by the Church, based on the precedent that it passes freely between mother and fetus during pregnancy (2).
Michael Auerbach, MD

David Green, MD, PhD Northwestern University Medical School Chicago, Illinois 60611
To the Editors: In their excellent review of the management of the severely anemic Jehovah's Witness patient, Mann and colleagues (1) inaccurately report that "the use of adjunctive hyperbaric oxygen therapy is not indicated in the management of anemic Jehovah's Witnesses because toxicity precludes its prolonged use." This conflicts with reports supporting the use of such therapy in anemic patients with severe blood loss who are unable, either on medical or religious grounds, to receive blood products. Amonic and colleagues (2) first reported the successful use of hyperbaric oxygen therapy in hemorrhagic shock in 1969. Hart and colleagues (3) recently reviewed 26 anemic patients with exceptionally severe blood loss and class IV shock, reporting an overall survival of 70% using adjunctive hyperbaric oxygen therapy. Therapy was well tolerated and oxygen toxicity was not reported. Use of adjunctive hyperbaric oxygen therapy is endorsed by the Undersea and Hyperbaric Medical Society Committee (4), which periodically reviews and approves clinical applications of adjunctive hyperbaric oxygen therapy.
In six anemic patients with severe blood loss and shock, we found hyperbaric oxygen therapy to be beneficial and not to be required continuously. Hyperbaric oxygen therapy substantially enhances tissue oxygen delivery, reverses tissue oxygen debt, and saturates tissues with a high partial pressure of oxygen. At 66 feet of sea water or 3 atmospheres absolute, the plasma oxygen-carrying capacity alone is greater than 6 volumes percent, exceeding the normal arterial to venous oxygen extraction. Clinically, the effect of hyperbaric oxygen treatment exceeds the treatment time by using saturated tissue reserves. Treatment frequency depends on patient response and is usually tapered over days until the patient is stable. We believe that adjunctive hyperbaric oxygen therapy may have reduced the prolonged and complicated course the patient experienced by enhancing tissue oxygen delivery during the acute phase. Only through a good understanding of religious tenets, available therapy, and medicolegal issues can physicians appropriately manage these patients. To the Editors: In their comprehensive and very informative article on the management of severely anemic Jehovah's Witness patients, Mann and colleagues (1) mentioned desmopressin to reduce intraoperative and perioperative blood loss. Another drug, aprotinin, might be useful in such circumstances. Aprotinin has been used in heart surgery because it decreases blood loss and transfusion requirements by as much as 80% during cardiopulmonary bypass (2) . It probably acts by inhibiting kallikrein (3). Decreased production of kallikrein results in decreased factor Xlla generation, which in turn leads to diminished tissue plasminogen activator production (4). In addition, aprotinin is a serine protease inhibitor and thus directly neutralizes plasmin (3). The net result of decreased production and enhanced destruction of plasmin is a powerful antifibrinolytic effect. Furthermore, during cardiopulmonary bypass, aprotinin preserves platelet function by preventing the stripping of platelet lb receptor by enzymes such as plasmin, elastase, and calpain (5) .
These actions suggest that aprotinin may help Jehovah's Witnesses undergoing cardiac surgery and those who suffer from bleeding due to hyperfibrinolysis. In response: We appreciate the comments of Drs. Auerbach and Ballard regarding the use of intravenous iron dextran as a total dose infusion.
Amin U. Haq, MD
Dr. Green's statement that "albumin is considered acceptable by the Church" is incorrect. The Church leaves this decision up to the individual based on the precedent that it passes freely between mother and fetus, as per our discussion with a Watchtower spokesperson in New York.
Drs. Youn and Burns correctly point out that hyperbaric oxygen therapy has been used in severely anemic patients who refuse blood transfusion. Hart and colleagues' review (1) of 26 patients treated with hyperbaric oxygen, however, also mentions a 50% incidence of barotrauma, which was felt to reflect the number of treatments per day. A prospective study would offer more information about the potential benefit and risk of this expensive therapy in patients with severe anemia.
Dr. Haq brings up an interesting drug, aprotinin, which has been used and reported on mostly in Europe. We agree that the antifibrinolytic effects and platelet preservation properties of this drug might be of value in patients with extensive hemorrhage or disseminated intravascular coagulation. It is such a good antifibrinolytic agent, however, that clot has been reported on pulmonary artery catheters (2) . It is incompatible with corticosteroids, heparin, and the protein and lipid content of hyperalimentation. In fact, the Food and Drug Administration has not chosen to approve this drug and it has been withdrawn from the market.
Patients 9 Choices and the Medical Commons
To the Editors: The recent perspective by Mann and colleagues (1) describing the critical care of a Jehovah's Witness suggests that the patient's preference resulted in an excessive intensive care unit stay and cost. The authors failed to mention the price tag of this exercise in the application of alternative, less effective technology. The normal length of stay for a similar patient is 8 days with a reimbursement of $6879, according to the 1992 DRG Handbook. The complication of Pseudomonas aeruginosa pneumonia increases the length of stay to 13 days and the reimbursement to $14 429. Outlier status is achieved by 28 and 36 days, respectively. The cost for the 41 days of intensive care with mechanical ventiliation and a total hospital stay of 58 days for the patient described is likely to have exceeded $150 000 using conservative estimates.
I would suggest that, in addition to the ethical principles of beneficence and autonomy mentioned by the authors, a third ethical principle is raised, that of social justice. Should society be compelled to use precious resources in an inefficient fashion because of patient choice? The authors do an admirable job of discussing the physiology, cost, uncertain efficacy, and risks for each individual intervention but fail to acknowledge their apparent misuse of resources that might be better used for prenatal care or vaccination programs.
Society would do well to reevaluate its approach to patients who, by choice, refuse the standard of care in a given situation but are willing to submit themselves to expensive, risky, technological interventions that put themselves, the physician, and the hospital in jeopardy. Physicians increasingly are taking responsibility for their part in generating health care costs because of the urgent need to provide better services for more people at less expense. If we are ever to have a successful health care system for all, it is imperative that the patients (consumers) also begin to take responsibility for not unduly raising the stakes or "raiding the commons" (2, 3) . The personal choices in this case involved both refusal of accepted therapy and acceptance (or demand) of high-cost, intensive, high-technological care. Perhaps the restrictions inherent in a fixed global health care budget will be incompatible with this kind of self-determination.
There are many ways of making undue demands on joint resources, involving everything from self-neglect, poor health habits, over-reliance on alternative therapies, and refusal of the best available treatment. In each instance, the health care system eventually has to deal with more severe illness requiring higher expenditures.
Finding solutions to these problems will not be easy. Maybe it would be possible to tie choices of fully competent patients to individual financial responsibility for excess costs incurred. Currently, it is the health care providers, insurers, or "the commons" that bear the added expense.
Rifabutin-induced Ageusia
To the Editors: Ageusia, the loss of the sense of taste, is an infrequently reported adverse effect of antimicrobial use. We describe a patient who developed ageusia while receiving rifabutin therapy for Mycobacterium simiae pulmonary infection.
A 71-year-old white woman with cavitary lung disease had a transbronchial biopsy specimen that yielded Nocardia asteroides and M. simiae. She received sulfisoxazole for the former infection and clarithromycin and rifabutin for the latter. Six weeks after starting therapy with clarithromycin and rifabutin, she reported ageusia, arthralgias, and myalgias. Physical examination showed cachexia and mild skin hyperpigmentation. The patient had no edema, tenderness, or decreased range of joint motion. The leukocyte count was 3400 cells/mm 3 (with a normal differential); the erythrocyte sedimentation rate was 35 mm/h; the calcium level was 8.4 mg/dL; and the magnesium level was 2.0 mg/dL. The symptoms were attributed to rifabutin, which was then withdrawn. Two weeks later, ageusia had almost completely resolved. Rifabutin therapy was restarted, but within 2 days she reported worsening ageusia, myalgias, and arthralgias. Rifabutin therapy was discontinued and over the next few weeks her ageusia resolved.
Rifabutin is a rifamycin-like antimicrobial that reacts in vitro against M. avium-intracellulare and M. tuberculosis. Adverse effects include painless urine discoloration; flushing erythema of the upper trunk and head; influenza-like episodes characterized by fever, myalgia, and headache; arthritis-arthralgia syndrome; elevated transaminase levels; and renal impairment (1-3) . Ageusia has not been previously reported with rifabutin use.
Previous reports have attributed drug-induced ageusia to phenylbutazone, chlormezanone, baclofen, captopril, amphotericin B, griseofulvin, metronidazole, and lincomycin (4, 5). Although our patient was also taking sulfisoxazole and clarithromycin, the return of sense of taste followed by recurrence of ageusia after restarting rifabutin indicates that rifabutin was the probable cause. With its recent Food and Drug Administration approval, rifabutin will be increasingly used to treat and suppress M. avium complex infections in patients with the acquired immunodeficiency syndrome (AIDS), and clinicians should be aware of this potential adverse effect.
Paying for Kidney Donors
To the Editors: The recent important report by Sesso and colleagues (1) confirms that transplantation of kidneys from living, unrelated donors (LUDs) is at least as effective as transplantation from cadaveric donors. The authors' conclusion, however, that "payment for the donor or 'rewarded gifting' is unacceptable" ignores a wealth of literature, which suggests that, under certain circumstances, financial incentives for living organ donation may indeed be reasonable.
Almost all agree that rampant commercialism, where the care of the donor is less important than the profit, is reprehensible (2). Yet, some have suggested that rewarded gifting, wherein the donor is compensated under strict controls without middlemen, may be acceptable. Perhaps the most extensive published experience comes from Reddy and colleagues in Madras (3, 4) . In India, because the supply of dialysis facilities and kidneys from cadaveric donors are extremely limited, the diagnosis of end-stage renal disease is for many the equivalent of a death sentence. This situation led the group in Madras (3) to ask "Do we buy or let die?" They decided to embark on a program that accepted LUDs, using a system of rewarded gifting. Under their program of tightly regulated, paid donation, excellent medical care is provided for the donor in addition to 3 years of medical insurance. In more than 300 transplantations of kidneys from LUDs, they have achieved excellent results with no donor mortality and no decrease in the number of living, related donors (3, 4) . Other prominent transplant physicians have also concluded that rewarded gifting may be acceptable, at least in some parts of the world (2) . Even the Transplantation Society (5), which strongly opposes commercialization, agrees that "reimbursement for loss of work earnings and any other expenses related to the donation is acceptable."
As we encounter new and complex ethical problems in medicine, we must remain open-minded and be willing to explore creative new plans and ideas. Dogmatic statements that ignore the views and experience of others should be avoided.
In response: The use of financial incentives for donors is among the methods that have been recently debated in an effort to improve organ supply for kidney transplantation (1). The Transplantation Society guidelines for the donation of kidneys by LUDs forbid payment to the donor by the recipient, the recipient's relatives, or any supporting organization (2) .
The main arguments against donor financial compensation are that 1) it is morally reprehensible and would damage the public's will to act altruistically; 2) it would lead to preferential distribution of organs to the wealthy and might lead to coercion and exploitation; 3) it might stimulate organ donation from persons who are not medically suitable; 4) it might lead to a decreased effort to achieve more suitable donor-recipient matches; and 5) it could impair the development of cadaveric organ transplantation programs.
In our study, we found that LUDs may be indicated for recipients for whom neither a living, related nor a cadaveric donor is available. However, before we resort to financial incentives for the donor, more urgent alternatives exist to increase the supply of organs. Many more organ donors are available worldwide than are being accessed through existing organ procurement efforts. In the United States, the number of available donors could be increased by 80% (3). In developing countries, organ procurement could be better organized. In Brazil, lack of motivation and of efficiency of medical teams attending potential donors rather than lack of suitable organs seems to be the problem (4). Recent organ procurement efforts in Sao Paulo have significantly increased cadaveric organ transplantation activity. Currently, more than 80% of the approximately 120 kidney transplants done each year at Escola Paulista de Medicina are with cadaveric donors.
A major concern about the practice in India relates to donor selection. All donors were from the lower stratum of society and in great financial need. Their follow-up has been poor. In addition, the practice of transplantation of kidneys from LUDs may have impaired the development of living, related and cadaveric transplant programs in India.
If transplant physicians in India or elsewhere believe that paid donation is the only way to keep their patients alive, and they have community support, who are we to condemn them? The ethics of treating end-stage renal disease in Western culture may not apply in India (5). In our opinion, however, the benefits from direct payment for organs from LUDs in our country do not outweigh the ethical arguments against its practice.
Immunoradiometric Assays May Miss High Prolactin Levels
To the Editors: Measurement of serum prolactin levels is useful in differentiating prolactinoma from other causes of increased prolactin concentrations. Distinguishing between prolactinoma and a nonfunctioning pituitary adenoma, or even nonadenomatous disease, is important because dopamine agonist therapy may reduce tumor size in most macroprolactinomas but is largely ineffective in nonsecreting adenoma and nonadenomatous lesions (1) . Solid-phase sandwich radioimmunoassay (immunoradiometric assay) is frequently used to measure prolactin levels. "Results from immunoradiometric assay kits may be subject to the well-documented, high-dose "hook effect," or prozone effect, where extremely high serum concentrations of an antigen may paradoxically produce a lower response than expected and, on dilutions, produce a higher assay response (2) . We present a case that shows this phenomenon.
The patient was a 37-year-old man who developed visual disturbances and was found, using a high-resolution computerized tomographic scan, to have a large infiltrating pituitary adenoma of 5.5 x 4 x 3 cm. Before surgery, 17 serial prolactin measurements in duplicate were determined by a one-step immunoradiometric assay (Immunocorp; Montreal, Canada) and showed values from 41 to 48 jug/L (normal, <14 /JLgJL). The patient had incomplete transsphenoidal resection of his large cystic tumor. Pathological and immunocytochemical studies showed typical characteristics of prolactinoma, where all cells were positive with anti-prolactin serum. Dilution studies done on the patient's serum obtained before surgery showed an initial prolactin level of 31 795 ^ig/L. After 15 months of treatment with bromocriptine, 2.5 mg thrice daily, the tomographic scan showed a marked decrease in the size of the adenoma, and prolactin levels diminished from 11 171 to 227 /xg/L.
The development of newer techniques for measuring prolactin, such as the immunoradiometric assay, has emphasized the gain in efficiency that occurs when separate incubation steps followed by washes are eliminated. In our experience, the accuracy and reproducibility of this assay system appears satisfactory, although results using immunoradiometric assay kits may be subject to the hook effect, a problem of which users may be unaware (2) . The effect is thought to be caused by an excess of antigen that saturates the recognition sites on both the unlabeled and labeled antibodies, inhibiting formation of the antigen-antibody sandwich. Because the amount of antigen (prolactin) in the complex is assumed to be proportional to the amount of radioactivity present, falsely low results would be obtained. The "hook effect" has been recently documented with other immunoradiometric assays (3, 4) . A case report illustrating high-dose hook effect for prolactin determination has not been previously reported. However, Haller and colleagues (5) showed that this effect, when induced in vitro, can be eliminated by using a two-step assay or by doing the analysis at two sample dilutions (5) . Such a procedure should be done in patients with a prolactinoma.
